Research graph
References from A drug repurposing method based on inhibition effect on gene regulatory network. Local targets link to admitted publications; unresolved targets remain external evidence.
The road ahead in genetics and genomics
10.1038/s41576-020-0272-6 · 2020 · External reference
The next generation of evidence-based medicine
10.1038/s41591-022-02160-z · 2023 · External reference
Why 90% of clinical drug development fails and how to improve it?
10.1016/j.apsb.2022.02.002 · 2022 · External reference
Improving the odds of drug development success through human genomics: modelling study
10.1038/s41598-019-54849-w · 2019 · External reference
New drug development in the United States from 1963 to 1999
10.1067/mcp.2001.115132 · 2001 · External reference
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
10.1001/jama.2020.1166 · 2020 · External reference
Drug repurposing: progress, challenges and recommendations
10.1038/nrd.2018.168 · 2019 · External reference
Machine learning approaches and databases for prediction of drug-target interaction: a survey paper
10.1093/bib/bbz157 · 2021 · External reference
A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2
2022 · External reference
Learning from low-rank multimodal representations for predicting disease-drug associations
10.1186/s12911-021-01648-x · 2021 · External reference
HiSCF: leveraging higher-order structures for clustering analysis in biological networks
10.1093/bioinformatics/btaa775 · 2021 · External reference
Signature-based approaches for informed drug repurposing: targeting CNS disorders
10.1038/s41386-020-0752-6 · 2021 · External reference
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
10.1038/s41421-020-0153-3 · 2020 · External reference
Pathway-based drug-repurposing schemes in cancer: the role of translational bioinformatics
10.3389/fonc.2020.605680 · 2020 · External reference
The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease
10.1126/science.1132939 · 2006 · External reference
The connectivity map: a new tool for biomedical research
10.1038/nrc2044 · 2007 · External reference
Drug repositioning: a machine-learning approach through data integration
10.1186/1758-2946-5-30 · 2013 · External reference
PharmOmics: a species- and tissue-specific drug signature database and gene-network-based drug repositioning tool
2022 · External reference
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease
10.1126/scitranslmed.3002648 · 2011 · External reference
Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network
10.1093/bioinformatics/btab191 · 2021 · External reference
"A new computational drug repurposing method using established disease-drug pair knowledge," (in eng)
10.1093/bioinformatics/btz156 · 2019 · External reference
Discovery and preclinical validation of drug indications using compendia of public gene expression data
10.1126/scitranslmed.3001318 · 2011 · External reference
"Inferring drug-disease associations based on known protein complexes
10.1186/1755-8794-8-s2-s2 · 2015 · External reference
A novel computational approach for drug repurposing using systems biology
10.1093/bioinformatics/bty133 · 2018 · External reference
Predicting drug-disease associations and their therapeutic function based on the drug-disease association bipartite network
10.1016/j.ymeth.2018.06.001 · 2018 · External reference
Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks
10.1186/s12859-016-1336-7 · 2016 · External reference
HINGRL: predicting drug-disease associations with graph representation learning on heterogeneous information networks
2021 · External reference
Network-based approach to prediction and population-based validation of in silico drug repurposing
10.1038/s41467-018-05116-5 · 2018 · External reference
Network-based in silico drug efficacy screening
10.1038/ncomms10331 · 2016 · External reference
Systems pharmacology-based integration of human and mouse data for drug repurposing to treat thoracic aneurysms
10.1172/jci.insight.127652 · 2019 · External reference
"Pathway-based drug repositioning using causal inference
10.1186/1471-2105-14-s16-s3 · 2013 · External reference
gene2drug: a computational tool for pathway-based rational drug repositioning
10.1093/bioinformatics/btx800 · 2018 · External reference
The extraction of drug-disease correlations based on module distance in incomplete human interactome
10.1186/s12918-016-0364-2 · 2016 · External reference
Prediction of novel drugs for hepatocellular carcinoma based on multi-source random walk
10.1109/tcbb.2016.2550453 · 2017 · External reference
Predicting potential drugs for breast cancer based on miRNA and tissue specificity
10.7150/ijbs.23350 · 2018 · External reference
Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways
10.1371/journal.pcbi.1008696 · 2021 · External reference
Subpathway analysis based on signaling-pathway impact analysis of signaling pathway
10.1371/journal.pone.0132813 · 2015 · External reference
SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs
2021 · External reference
"PATHOME-Drug: a subpathway-based poly-pharmacology drug-repositioning method," (in eng)
2021 · External reference
The Comparative Toxicogenomics Database's 10th Year Anniversary: update 2015
10.1093/nar/gku935 · 2015 · External reference
Transcriptome profile of human colorectal adenomas
10.1158/1541-7786.mcr-07-0267 · 2007 · External reference
"A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics," (in eng)
10.1007/s10585-010-9305-4 · 2010 · External reference
Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy
10.1016/j.ajpath.2010.10.020 · 2011 · External reference
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer
10.1371/journal.pone.0027656 · 2011 · External reference
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis
10.1093/carcin/bgt208 · 2013 · External reference
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women
10.1371/journal.pone.0063204 · 2013 · External reference
Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer
10.1002/ijc.25704 · 2011 · External reference
Gene expression-based classification of non-small cell lung carcinomas and survival prediction
10.1371/journal.pone.0010312 · 2010 · External reference
Identification of regulatory SNPs associated with genetic modifications in lung adenocarcinoma
10.1186/s13104-015-1053-8 · 2015 · External reference
Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation
10.1186/ar4526 · 2014 · External reference
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain
10.1152/physiolgenomics.00208.2006 · 2007 · External reference
limma powers differential expression analyses for RNA-sequencing and microarray studies
10.1093/nar/gkv007 · 2015 · External reference
Gene set analysis for GWAS: assessing the use of modified Kolmogorov-Smirnov statistics
10.1515/sagmb-2013-0015 · 2014 · External reference
Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery
10.1186/s12864-016-2737-8 · 2016 · External reference
Trichostatin A induces p53-dependent endoplasmic reticulum stress in human colon cancer cells
2019 · External reference
Trichostatin A suppresses lung adenocarcinoma development in Grg1 overexpressing transgenic mice
10.1016/j.bbrc.2015.06.090 · 2015 · External reference
Trichostatin A inhibits proliferation of triple negative breast cancer cells by inducing cell cycle arrest and apoptosis
10.4149/neo_2018_181212n476 · 2018 · External reference
Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell
10.1016/j.bbrc.2016.05.139 · 2016 · External reference
Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition
10.1139/cjpp-2021-0577 · 2022 · External reference
Anisomycin sensitizes non-small-cell lung cancer cells to chemotherapeutic agents and epidermal growth factor receptor inhibitor via suppressing PI3K/Akt/mTOR
10.1111/fcp.12641 · 2021 · External reference
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
2019 · External reference
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
10.1053/j.gastro.2004.07.011 · 2004 · External reference
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis
10.2337/dc11-0512 · 2011 · External reference
Metformin in cancer prevention and therapy
2014 · External reference
Pyrvinium pamoate in the treatment of pinworm infection (enterobiasis) in the home
10.1016/s0022-3476(62)80042-0 · 1962 · External reference
Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis
10.1371/journal.pone.0101969 · 2014 · External reference
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
10.1158/0008-5472.can-08-1385 · 2008 · External reference
Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer
10.1016/j.bcp.2020.113960 · 2020 · External reference
Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium
10.1021/cb400759d · 2014 · External reference
Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration
10.18632/oncotarget.5615 · 2015 · External reference
"Phase II study of hycanthone in patients with advanced colorectal carcinoma," (in eng)
1983 · External reference
Lucanthone and its derivative hycanthone inhibit apurinic endonuclease-1 (APE1) by direct protein binding
10.1371/journal.pone.0023679 · 2011 · External reference
Biochemical target isolation for novices: affinity-based strategies
10.1016/j.chembiol.2010.05.015 · 2010 · External reference
Potential therapeutic targets and small molecular drugs for pediatric B-precursor acute lymphoblastic leukemia treatment based on microarray data
10.3892/ol.2017.6343 · 2017 · External reference
Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening
10.1016/j.chembiol.2007.02.004 · 2007 · External reference
Oncogenic PI3K deregulates transcription and translation
10.1038/nrc1753 · 2005 · External reference
Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-β-catenin axis
10.1016/j.bbrc.2016.02.120 · 2016 · External reference
Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy
10.1038/s41598-018-22257-1 · 2018 · External reference
